Abstract
ADMINISTRATION of antilymphocytic serum (ALS) or globulin (ALG) by subcutaneous1, intramuscular2, intraperitoneal3 or intravenous4 injection has been shown to prolong survival of allografts in various experimental systems. No data seem to be available, however, concerning the relative effect of administering the same dose of ALG by different routes on a particular graft in one species. We have compared the effect of daily intramuscular, intraperitoneal and intravenous injection, and continuous intravenous infusion, of ALG on skin allograft survival in rats.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
